—
Dufry: Stock in late trading yesterday with impressive intraday reversal, from conspicuous purchases in the call warrants DUFAMZ as DUFWJB accompanied.
Holcim: Credit Suisse at rates of CHF 44.90 unhappy on the tactical buy recommendation stopped out. Arch rival UBS used to do this before.
Datwyler: Stifel goes to BUY (Hold) up to CHF 385.
Geberit: Share for Stifel a buy up to CHF 875 (765) France or Great Britain could become Germany’s next growth miracle.
Implenia: Research Partners cut to 22 (25) Fr. with HOLD. Thin equity ratio does not allow any further mishaps.
Kudelski: Research Partners increase to 4.20 (4) Fr. with HOLD. New business model less capital intensive and with a more flexible cost structure.
Kuehne + Nagel: Bank of America goes to NEUTRAL (underperform) to 400 (300) Fr. Approaches in air and ocean freight are likely to remain high into next year.
Lem: Research Partners increase to 2150 (1950) Fr. with HOLD.
Mobimo: World’s largest asset manager Blackrock buys heavily, recently holds 5.3pc in the real estate investment company.
Novartis: Develops its own position in gene therapy with the takeover of Arctos Medical. As usual, no information on the purchase price. Subsidiary Sandoz is subject to patent litigation against Amgen.
Partners Group: Investors break down the door at the venture capital specialist. Fourth private equity buyout program with total commitments of CHF 15 billion
Roche: Loss of market share for drugs such as Herceptin, Avastin and Rituxan to the end within the framework of the company’s own specifications, as reported by the British Barclays. No unpleasant surprises should be expected from this point of view. Remains for OVERWEIGHT up to 395 Fr.
Swatch Group: Royal Bank of Canada cuts to CHF 270 (300) with SECTOR PERFORM. This takes into account the recent negative news from China.
Ypsomed: Research Partners go to BUY (Hold) to 175 (160) Fr.
Zug Estates: ZKB lowers to MARKET WEIGHTS (overweight). Longer-term outlook is intact, but no price drivers can be seen in the short term.
Derivatives: With the exception of smaller sales in the ODAASV knock-out call on the DAX hardly anything going on.
–
